No evidence for the JAK2 (V617F) or JAK2 exon 12 mutations in primary mediastinal large B-cell lymphoma

Diagnostic Molecular Pathology

Volumn 18, Issue 3, 2009, Pages 144-149

  Wu, David ^a   Dutra, Bethany ^a   Lindeman, Neal ^a   Takahashi, Hidenobu ^b   Takeyama, Kunihiko ^b   Harris, Nancy L ^c   Pinkus, Geraldine S ^a   Longtine, Janina ^a   Shipp, Margaret ^b   Kutok, Jeffery L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ARMS; Capillary electrophoresis; Hodgkin lymphoma; JAK2; JAK2 (V617F); JAK2 exon 12 mutation; Mediastinal large B cell lymphoma

Indexed keywords

JANUS KINASE 2;

ARTICLE; B CELL LYMPHOMA; CANCER MORPHOLOGY; CONTROLLED STUDY; EXON; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HODGKIN DISEASE; HUMAN; HUMAN CELL; PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EXONS; GENE FREQUENCY; HUMANS; JANUS KINASE 2; LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC; MEDIASTINAL NEOPLASMS; MUTATION, MISSENSE;

EID: 69749086422     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/PDM.0b013e3181855c7f     Document Type: Article

References (21)

1. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102:3871. (Pubitemid 37486965)
2. Perrone T, Frizzera G, Rosai J. Mediastinal diffuse large-cell lymphoma with sclerosis. A clinicopathologic study of 60 cases. Am J Surg Pathol. 1986;10:176. (Pubitemid 16055156)
3. Barth TF, Leithauser F, Moller P. Mediastinal B-cell lymphoma, a lymphoma type with several characteristics unique among diffuse large B-cell lymphomas. Ann Hematol. 2001;80(suppl 3):B49. (Pubitemid 33135856)
4. Lamarre L, Jacobson JO, Aisenberg AC, et al. Primary large cell lymphoma of the mediastinum. A histologic and immunophenotypic study of 29 cases. Am J Surg Pathol. 1989;13:730. (Pubitemid 19201943)
5. Barth TF, Leithauser F, Joos S, et al. Mediastinal (thymic) large B-cell lymphoma: where do we stand? Lancet Oncol. 2002;3:229.
6. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851. (Pubitemid 37152922)
7. Bentz M, Barth TF, Bruderlein S, et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer. 2001;30:393. (Pubitemid 32216330)
8. Joos S, Granzow M, Holtgreve-Grez H, et al. Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int J Cancer. 2003;103:489. (Pubitemid 36020223)
9. Joos S, Kupper M, Ohl S, et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res. 2000;60:549. (Pubitemid 30094549)
10. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162. (Pubitemid 41291734)
11. Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008;111:1686. (Pubitemid 351213460)
12. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99:4283.
13. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459. (Pubitemid 46193073)
14. Melzner I, Weniger MA, Menz CK, et al. Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Leukemia. 2006;20:157.
15. Melzner I, Bucur AJ, Bruderlein S, et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood. 2005;105:2535. (Pubitemid 40387056)
16. Alexander WS, Starr R, Metcalf D, et al. Suppressors of cytokine signaling (SOCS): negative regulators of signal transduction. J Leukoc Biol. 1999;66:588. (Pubitemid 29489885)
17. Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 1997;387:921. (Pubitemid 27289595)
18. Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917.
19. Koyama M, Nagai H, Bando K, et al. Localization of a target region of allelic loss to a 1-cM interval on chromosome 16p.13.13 in hepatocellular carcinoma. Jpn J Cancer Res. 1999;90:951. (Pubitemid 29500433)
20. Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 2001;28:29. (Pubitemid 32405812)
21. Engelman JA, Mukohara T, Zejnullahu K, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest. 2006;116:2695. (Pubitemid 44511633)